Bioceltix to debut on NewConnect

Since its establishment, Bioceltix has already raised several million USD from private investors and public grants. Shareholders believe in our vision – as one of the first companies in the world, we plan to go through the full authorization procedure with the European Medicines Agency for a veterinary medicinal product using stem cells as active substance. This is a real breakthrough in veterinary medicine that the market has been looking forward to for years. We are the first company that, along with conducting research on stem cell efficacy, has simultaneously developed the technology of their large-scale growing.

Before we decided to go public, we obviously considered debt financing. However, it is no secret that companies at an early stage of development that do not generate positive cash flows are generally unable to service such debt and are not creditworthy. For biotech companies with additional research-related risks inherent in the industry, it is extremely difficult to obtain funding. On the Polish capital market there are still relatively few investors who are willing to accept this level of risk, especially when combined with the lack of liquidity characteristic of private investments. This is where the stock exchange can be really helpful.

We have opted for stock exchange debut not only because of the possibility of obtaining additional financing, but also for the sake of added value. As a listed company, we become more transparent and credible. This is not only important for financial investors, but also helps us build a strong position in negotiations with potential industry partners. As a listed company, we are able to significantly increase our circle of potential investors.